AstraZeneca’s Camizestrant Extends Survival in ESR1-Mutant Breast Cancer
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
AstraZeneca
Advertisement
AstraZeneca’s Imfinzi Wins FDA Approval in NMIBC
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
AstraZeneca and Daiichi Sankyo Advance Enhertu in Tumour-Agnostic Oncology
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for...
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
AstraZeneca Unveils Major ASCO 2026 Cancer and Rare Disease Data
CAMBRIDGE, UK, 22 May 2026 AstraZeneca announced a major scientific showcase at the upcoming ASCO Annual Meeting 2026, highlighting...
Advertisements
AstraZeneca’s FASENRA Wins FDA Approval for HES
WILMINGTON, Del., May 14, 2026 AstraZeneca announced that the U.S. Food and Drug Administration has approved FASENRA® (benralizumab) for...
AstraZeneca VOLGA Trial Boosts Bladder Cancer Survival
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
AstraZeneca Reports Positive Phase III Results for Eneboparatide in HypoPT
PRAGUE, Czech Republic, May 12, 2026 AstraZeneca and Alexion announced positive Phase III clinical trial results for eneboparatide (AZP-3601),...
AstraZeneca TRUQAP Gains FDA Panel Support in Prostate Cancer
WASHINGTON, D.C., April 30, 2026 AstraZeneca announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC)...
Paradigm Health, FDA Advance Real-Time Trial Review Model
WASHINGTON & COLUMBUS, OHIO, April 28, 2026 Paradigm Health has announced a landmark research collaboration with the U.S. Food...
Advertisement
